Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Weighing up efficacy data and QoL in clinical decision making

Joe O'Sullivan • 29 Nov 2018
ESMO 2018
Genitourinary Cancer Prostate Cancer
ERA 223

Joe O’Sullivan, MD, of Queen’s University Belfast, Belfast, UK, first discusses the importance of conducting large randomized trials to identify the toxic effects of anti-cancer therapies, before raising concerns on adherence to guidelines when treating patients. Prof. O’Sullivan also questions the current rationale behind weighing up the benefits and risks in the implementation of cancer therapies, and proposes suggestions on possible criteria for guidelines set by organizations. This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

More from Joe O'Sullivan

Biomarkers associated with PARPi response in patients with castration-resistant prostate cancer
0:58
Biomarkers associated with PARPi response in patients with castration-resistant prostate cancer
Joe O'Sullivan • 28 Jun 2022
Recent advances in mHSPC: 177Lu-PSMA-617, PROpel and biomarker-directed strategies
1:37
Recent advances in mHSPC: 177Lu-PSMA-617, PROpel and biomarker-directed strategies
Joe O'Sullivan • 28 Jun 2022
Role of the addition of docetaxel to ADT in mHSPC
1:19
Role of the addition of docetaxel to ADT in mHSPC
Joe O'Sullivan • 28 Jun 2022
UK prostate cancer challenges
1:26
UK prostate cancer challenges
Joe O'Sullivan • 8 Mar 2019

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals